EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON VAGINAL Candida spp. ISOLATION IN HIV-INFECTED COMPARED TO HIV-UNINFECTED WOMEN
Authors:
- Patrícia de Souza Bonfim-MendonçaPBPatrícia de Souza Bonfim-Mendonça
- Cristiane Suemi Shinobu-MesquitaCSCristiane Suemi Shinobu-Mesquita
- Fabrícia GimenesFGFabrícia Gimenes
- Maria Dalva de Barros CarvalhoMCMaria Dalva de Barros Carvalho
- Sandra Marisa PellosoSPSandra Marisa Pelloso
- Terezinha Inez Estivalet SvidzinskiTSTerezinha Inez Estivalet Svidzinski
- Marcia Edilaine Lopes ConsolaroMCMarcia Edilaine Lopes Consolaro
Open Access
- 1 April 2015
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 57 (2) , 169-174
Abstract
Vulvovaginal candidiasis (VVC) in HIV-infected women contributed to the impairment of their quality of life. The aim of this study was to evaluate the effect of highly active antiretroviral therapy (HAART) use on the vaginal Candida spp. isolation in HIV-infected compared to HIV-uninfected women. This cross-sectional study included 178 HIV-infected (HIV group) and 200 HIV-uninfected women (control) that were studied at the Specialized Assistance Service (SAE) for sexually transmitted diseases (STD)/AIDS of the city of Maringá, Brazil, from April 1 to October 30, 2011. The yeasts were isolated and identified by phenotypic and molecular methods. The in vitro antifungal susceptibility to fluconazole, itraconazole, nystatin and amphotericin B was tested by the reference microdilution method. Higher frequencies of total vaginal Candida spp. isolation were found in the HIV-infected group than in the control group. However, both groups showed a similar frequency of colonization and VVC. Although C. albicans was the most frequent and sensitive to azolics and polyenes in both HIV-infected and uninfected women, the emerging resistance of C. glabrata to amphotericin B in the HIV-infected women was observed. Although higher frequency of vaginal Candida spp. isolation had been observed in the HIV-infected than in HIV-uninfected women, colonization and VVC showed similar frequency in both groups, indicating that HAART appears to protect against vaginal colonization and VVC.Keywords
This publication has 22 references indexed in Scilit:
- Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infectionCochrane Database of Systematic Reviews, 2011
- HIV-1 molecular epidemiology evidence and transmission patterns in the Middle East and North AfricaSexually Transmitted Infections, 2010
- Bacterial Vaginosis and Vaginal Yeast, But Not Vaginal Cleansing, Increase HIV-1 Acquisition in African WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Vulvovaginal candidosisThe Lancet, 2007
- Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, BrazilInternational Journal of STD & AIDS, 2006
- Vaginal colonization with Candida spp. in human immunodeficiency virus – infected women: a cohort studyInternational Journal of STD & AIDS, 2006
- Prevalence and Exoenzyme Secretion by Candida Albicans Isolates from Oral and Vaginal Mucosas of HIV-Infected WomenMycopathologia, 2004
- A Monoclonal Antibody Directed against aCandida albicansCell Wall Mannoprotein Exerts Three Anti-C. albicansActivitiesInfection and Immunity, 2003
- Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus–infected women: Risk factors and severityObstetrics & Gynecology, 2003
- Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerationsAmerican Journal of Obstetrics and Gynecology, 1998